Symbols / MNPR
MNPR Chart
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 370.62M |
| Enterprise Value | 227.04M | Income | -19.44M | Sales | — |
| Book/sh | 21.25 | Cash/sh | 21.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -15.92 | PEG | — |
| P/S | — | P/B | 2.61 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 55.94 |
| Current Ratio | 56.10 | Debt/Eq | 0.07 | LT Debt/Eq | — |
| EPS (ttm) | -3.98 | EPS next Y | -3.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 09:00 | ROA | -17.99% |
| ROE | -26.54% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.68M |
| Shs Float | 4.53M | Short Float | 54.16% | Short Ratio | 4.06 |
| Short Interest | — | 52W High | 105.00 | 52W Low | 26.05 |
| Beta | 1.57 | Avg Volume | 267.44K | Volume | 181.19K |
| Target Price | $112.00 | Recom | None | Prev Close | $59.24 |
| Price | $55.46 | Change | -6.38% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$112.00
Mean price target
2. Current target
$52.04
Latest analyst target
3. DCF / Fair value
$-22.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$52.04
Low
$93.00
High
$130.00
Mean
$112.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | reit | BTIG | Buy → Buy | $104 |
| 2026-01-29 | main | Chardan Capital | Buy → Buy | $100 |
| 2026-01-14 | reit | BTIG | Buy → Buy | $104 |
| 2026-01-09 | init | Morgan Stanley | — → Overweight | $115 |
| 2025-11-14 | down | Raymond James | Strong Buy → Outperform | $123 |
| 2025-11-13 | main | Chardan Capital | Buy → Buy | $100 |
| 2025-11-10 | init | Leerink Partners | — → Outperform | $115 |
| 2025-11-09 | main | Chardan Capital | Buy → Buy | $100 |
| 2025-10-13 | init | Barclays | — → Overweight | $125 |
| 2025-10-06 | main | Raymond James | Strong Buy → Strong Buy | $142 |
| 2025-10-02 | main | Oppenheimer | Outperform → Outperform | $115 |
| 2025-09-29 | main | HC Wainwright & Co. | Buy → Buy | $105 |
| 2025-09-25 | main | Piper Sandler | Overweight → Overweight | $95 |
| 2025-09-25 | main | BTIG | Buy → Buy | $104 |
| 2025-09-25 | main | Chardan Capital | Buy → Buy | $85 |
| 2025-09-23 | init | Lake Street | — → Buy | $106 |
| 2025-09-16 | main | Chardan Capital | Buy → Buy | $60 |
| 2025-09-15 | reit | BTIG | Buy → Buy | $87 |
| 2025-09-09 | init | BTIG | — → Buy | $87 |
| 2025-09-03 | init | Raymond James | — → Strong Buy | $80 |
- Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance Wed, 11 Feb 2026 13
- $MNPR stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily Sun, 08 Feb 2026 15
- Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat ue, 03 Feb 2026 08
- BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus Mon, 02 Feb 2026 13
- Monopar Announces Pricing Of $19.2 Mln Public Offering Of Common Stock - Nasdaq ue, 23 Sep 2025 07
- Will MNPR stock benefit from infrastructure spending - Quarterly Trade Report & Technical Confirmation Trade Alerts - mfd.ru hu, 12 Feb 2026 15
- Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha Fri, 10 Oct 2025 07
- Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect? - Yahoo Finance ue, 21 Oct 2025 07
- Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat Wed, 04 Feb 2026 08
- Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus hu, 29 Jan 2026 08
- Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily Wed, 28 Jan 2026 14
- Will MNPR stock hit new highs in YEAR - Trade Signal Summary & Short-Term High Return Ideas - mfd.ru Fri, 13 Feb 2026 05
- Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - Yahoo Finance hu, 16 Oct 2025 07
- BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat Mon, 02 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8724 | — | — | ROBINSON CHANDLER D | Chief Executive Officer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 4326 | — | — | CITTADINE ANDREW | Chief Operating Officer | — | 2025-12-31 00:00:00 | D | nan |
| 2 | 1500 | — | Purchase at price 69.95 per share. | VU QUAN ANH | Chief Financial Officer | — | 2025-12-26 00:00:00 | D | 104925.0 |
| 3 | 5121 | — | Sale at price 67.06 - 68.09 per share. | KLAUSNER ARTHUR J | Director | — | 2025-12-18 00:00:00 | D | 343889.0 |
| 4 | 8726 | — | — | ROBINSON CHANDLER D | Chief Executive Officer | — | 2025-09-30 00:00:00 | D | nan |
| 5 | 4327 | — | — | CITTADINE ANDREW | Chief Operating Officer | — | 2025-09-30 00:00:00 | D | nan |
| 6 | 550229 | — | Sale at price 63.61 per share. | TACTIC PHARMA, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-24 00:00:00 | I | 34999957.0 |
| 7 | 16800 | — | Sale at price 40.00 per share. | STARR CHRISTOPHER M | Director | — | 2025-07-14 00:00:00 | D | 672020.0 |
| 8 | 16800 | — | Conversion of Exercise of derivative security at price 0.00 per share. | STARR CHRISTOPHER M | Director | — | 2025-07-14 00:00:00 | D | 84.0 |
| 9 | 8904 | — | Sale at price 40.00 per share. | TSUCHIMOTO-EVANS KIM R | Director | — | 2025-07-14 00:00:00 | D | 356171.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.16M | -8.83M | -10.54M | -9.13M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.59M | -8.40M | -10.52M | -9.10M |
| EBITDA | -16.16M | -8.83M | -10.54M | -9.13M |
| EBIT | -16.16M | -8.83M | -10.54M | -9.13M |
| NetInterestIncome | 404.02K | 429.04K | 21.24K | 24.02K |
| InterestIncome | 404.02K | 429.04K | 21.24K | 24.02K |
| NormalizedIncome | -15.59M | -8.40M | -10.52M | -9.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.59M | -8.40M | -10.52M | -9.10M |
| TotalExpenses | 16.16M | 8.83M | 10.54M | 9.13M |
| TotalOperatingIncomeAsReported | -16.16M | -8.83M | -10.54M | -9.13M |
| DilutedAverageShares | 3.79M | 2.76M | 2.54M | 2.49M |
| BasicAverageShares | 3.79M | 2.76M | 2.54M | 2.49M |
| DilutedEPS | -4.11 | -3.04 | -4.15 | -3.65 |
| BasicEPS | -4.11 | -3.04 | -4.15 | -3.65 |
| DilutedNIAvailtoComStockholders | -15.59M | -8.40M | -10.52M | -9.10M |
| NetIncomeCommonStockholders | -15.59M | -8.40M | -10.52M | -9.10M |
| NetIncome | -15.59M | -8.40M | -10.52M | -9.10M |
| NetIncomeIncludingNoncontrollingInterests | -15.59M | -8.40M | -10.52M | -9.10M |
| NetIncomeContinuousOperations | -15.59M | -8.40M | -10.52M | -9.10M |
| PretaxIncome | -15.59M | -8.40M | -10.52M | -9.10M |
| OtherIncomeExpense | 171.28K | |||
| OtherNonOperatingIncomeExpenses | 171.28K | |||
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 404.02K | 429.04K | 21.24K | 24.02K |
| InterestIncomeNonOperating | 404.02K | 429.04K | 21.24K | 24.02K |
| OperatingIncome | -16.16M | -8.83M | -10.54M | -9.13M |
| OperatingExpense | 16.16M | 8.83M | 10.54M | 9.13M |
| ResearchAndDevelopment | 13.01M | 5.60M | 7.59M | 6.49M |
| SellingGeneralAndAdministration | 3.16M | 3.23M | 2.95M | 2.63M |
| GeneralAndAdministrativeExpense | 3.16M | 3.23M | 2.95M | 2.63M |
| OtherGandA | 3.16M | 3.23M | 2.95M | 2.63M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.10M | 2.98M | 2.59M | 2.52M |
| ShareIssued | 6.10M | 2.98M | 2.59M | 2.52M |
| TotalDebt | 0.00 | 8.41K | 0.00 | |
| TangibleBookValue | 55.04M | 5.59M | 10.09M | 18.94M |
| InvestedCapital | 55.04M | 5.59M | 10.09M | 18.94M |
| WorkingCapital | 55.04M | 5.58M | 10.04M | 18.94M |
| NetTangibleAssets | 55.04M | 5.59M | 10.09M | 18.94M |
| CapitalLeaseObligations | 0.00 | 8.41K | 0.00 | |
| CommonStockEquity | 55.04M | 5.59M | 10.09M | 18.94M |
| TotalCapitalization | 55.04M | 5.59M | 10.09M | 18.94M |
| TotalEquityGrossMinorityInterest | 55.04M | 5.59M | 10.09M | 18.94M |
| StockholdersEquity | 55.04M | 5.59M | 10.09M | 18.94M |
| GainsLossesNotAffectingRetainedEarnings | 35.99K | -14.13K | 8.94K | -3.16K |
| OtherEquityAdjustments | 35.99K | -14.13K | 8.94K | -3.16K |
| RetainedEarnings | -75.79M | -60.21M | -51.80M | -41.29M |
| AdditionalPaidInCapital | 130.79M | 65.81M | 61.87M | 60.22M |
| CapitalStock | 6.10K | 2.98K | 12.95K | 12.60K |
| CommonStock | 6.10K | 2.98K | 12.95K | 12.60K |
| TotalLiabilitiesNetMinorityInterest | 5.25M | 1.76M | 3.14M | 1.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 8.41K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 8.41K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 8.41K | 0.00 | |
| CurrentLiabilities | 5.25M | 1.76M | 3.13M | 1.58M |
| PayablesAndAccruedExpenses | 5.25M | 1.76M | 3.13M | 1.58M |
| CurrentAccruedExpenses | 3.00M | 0.00 | ||
| Payables | 2.25M | 1.76M | 3.13M | 1.58M |
| AccountsPayable | 2.25M | 1.76M | 3.13M | 1.58M |
| TotalAssets | 60.29M | 7.35M | 13.23M | 20.52M |
| TotalNonCurrentAssets | 0.00 | 12.65K | 61.23K | 0.00 |
| NetPPE | 0.00 | 12.65K | 61.23K | 0.00 |
| GrossPPE | 0.00 | 12.65K | 61.23K | 0.00 |
| OtherProperties | 12.65K | 61.23K | ||
| BuildingsAndImprovements | 12.65K | 61.23K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 60.29M | 7.33M | 13.17M | 20.52M |
| OtherCurrentAssets | 78.87K | 66.43K | 45.98K | 217.75K |
| CashCashEquivalentsAndShortTermInvestments | 60.21M | 7.27M | 13.12M | 20.30M |
| OtherShortTermInvestments | 14.40M | 0.00 | 4.93M | 0.00 |
| CashAndCashEquivalents | 45.82M | 7.27M | 8.19M | 20.30M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.40M | -7.86M | -7.23M | -7.32M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 59.40M | 2.07M | 109.34K | 10.93M |
| EndCashPosition | 45.82M | 7.27M | 8.19M | 20.30M |
| BeginningCashPosition | 7.27M | 8.19M | 20.30M | 16.74M |
| EffectOfExchangeRateChanges | 494.00 | -16.80K | -3.48K | 4.62K |
| ChangesInCash | 38.55M | -903.32K | -12.11M | 3.56M |
| FinancingCashFlow | 59.29M | 2.03M | 32.87K | 10.88M |
| CashFlowFromContinuingFinancingActivities | 59.29M | 2.03M | 32.87K | 10.88M |
| NetOtherFinancingCharges | -104.22K | -46.97K | -76.63K | -63.25K |
| ProceedsFromStockOptionExercised | 84.00 | 0.00 | 169.00 | 17.48K |
| NetCommonStockIssuance | 59.40M | 2.07M | 109.34K | 10.93M |
| CommonStockIssuance | 59.40M | 2.07M | 109.34K | 10.93M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -14.34M | 4.93M | -4.92M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -14.34M | 4.93M | -4.92M | 0.00 |
| NetInvestmentPurchaseAndSale | -14.34M | 4.93M | -4.92M | 0.00 |
| SaleOfInvestment | 985.73K | 12.81M | 0.00 | |
| PurchaseOfInvestment | -15.32M | -7.88M | -4.92M | 0.00 |
| OperatingCashFlow | -6.40M | -7.86M | -7.23M | -7.32M |
| CashFlowFromContinuingOperatingActivities | -6.40M | -7.86M | -7.23M | -7.32M |
| ChangeInWorkingCapital | 3.49M | -1.35M | 1.65M | 317.77K |
| ChangeInOtherWorkingCapital | 4.24K | -4.24K | ||
| ChangeInOtherCurrentAssets | -21.79K | -20.41K | 171.75K | -86.20K |
| ChangeInPayablesAndAccruedExpense | 3.51M | -1.33M | 1.48M | 403.97K |
| ChangeInAccruedExpense | 3.00M | 0.00 | ||
| ChangeInPayable | 506.79K | -1.33M | 1.48M | 403.97K |
| ChangeInAccountPayable | 506.79K | -1.33M | 1.48M | 403.97K |
| OtherNonCashItems | 4.55M | |||
| StockBasedCompensation | 1.14M | 1.90M | 1.64M | 1.47M |
| NetIncomeFromContinuingOperations | -15.59M | -8.40M | -10.52M | -9.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MNPR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|